Pfizer ends development of potential pill obesity treatment

Google News RSS

• https://news.google.com/rss/search?q=pfizer-ends-development-of-potential-pill-obesity-treatment

Latest Articles Fetched Here

• Pfizer ends development of potential pill obesity treatment  AP News
• Pfizer ends development of weight-loss pill danuglipron  Reuters
• Pfizer scraps daily weight loss pill after liver injury in one patient  CNBC
• Pfizer ends development of weight-loss pill after patient's liver injury  upi.com
• Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity  statnews.com
• Pfizer ends testing on once-daily weight-loss pill treatment  TODAY.com
• Pfizer amps up push into obesity treatments with $4.9B deal for Metsera  Newsday
• Experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugar, Eli Lilly says  CNN
• Pfizer ends development of weight-loss pill danuglipron  CTV News
• Pfizer ends development of promising obesity pill after safety concerns  Business Standard
• Will China’s home-grown obesity drugs reshape global weight loss market?  Inquirer.net
• Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk  Newsday
• Meta faces historic antitrust trial that could force it to break off Instagram, WhatsApp  The Boston Globe
• Safety worries spur Pfizer to drop another obesity pill  BioPharma Dive
• Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer  CNBC
• Pfizer buys back into obesity drug chase with $4.9B Metsera deal  BioPharma Dive
• Pfizer doubles down on weight-loss treatments with up to $7.3 billion Metsera buyout  Reuters
• Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial  BioPharma Dive
• Pfizer drops twice-daily version of obesity pill over side effects  Reuters
• Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.  BioPharma Dive
• Lilly stops trial of muscle-sparing obesity drug  BioPharma Dive
• Pfizer (PFE) Advances Weight-Loss Pill Danuglipron in Race to Lucrative Market  Bloomberg.com
• Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera  CNBC
• Novo abruptly ends obesity drug deal with Hims  BioPharma Dive
• The race to launch a pill for weight loss  SWI swissinfo.ch
• Pfizer stops commercialization of hemophilia gene therapy Beqvez  Reuters
• Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side Effects  Investopedia
• Obesity Drug Stocks: Where to Invest Now  Morningstar Canada
• Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal  Reuters
• 7 Best Weight Loss Drug Stocks to Buy in 2025  US News Money
• Layoff Tracker: Voyager Loses 30 Employees After Novartis Prunes Deal  BioSpace
• The top 20 pharma companies by 2023 revenue  Fierce Pharma
• FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval  BioSpace
• Markets News, Sep. 22, 2025: Dow, S&P 500, Nasdaq Set New All-Time Highs; Nvidia Shares Rise on OpenAI Partnership  Investopedia
• Pipeline  Pfizer
• Lilly pill shows up to 8% weight loss, lowers blood sugar in diabetes patients  India Today
• The top 15 blockbuster patent expirations coming this decade  Fierce Pharma
• Pfizer Wins $10 Billion Bidding War for Obesity Drug Maker Metsera  Zoom Bangla News